Regencell Bioscience's 15min chart signals bearish trend with KDJ Death Cross and Marubozu.

As per Regencell Bioscience's 15-minute chart, a KDJ Death Cross and a Bearish Marubozu pattern emerged on October 9, 2025, at 14:15. This indicates a shift in momentum, with the stock price trending downwards and potentially continuing to decline. Sellers are currently in control of the market, and the bearish momentum is expected to persist.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has once again captivated the financial markets with its dramatic stock price fluctuations. The biotech company, which combines traditional Chinese medicine with modern biomedical approaches, has experienced a rollercoaster ride, soaring from $1 to $84 before plummeting below $10. Despite its volatility, the stock has shown renewed buying interest, climbing above $20 after consolidating near $12 Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].

On October 9, 2025, at 14:15, a KDJ Death Cross and a Bearish Marubozu pattern emerged on Regencell's 15-minute chart, indicating a shift in momentum. The stock price has been trending downwards, with sellers currently in control of the market. This bearish momentum is expected to persist, signaling a potential decline in the stock price Regencell Bioscience Holdings Ltd RGC^[2].

Regencell's origins are deeply personal, stemming from the health recovery story of COO James Chung. The company's mission is to integrate traditional Chinese medicine with modern biomedical approaches, particularly for neurodegenerative and neuropsychological disorders. Despite its market capitalization of around $10 billion, the company remains lean, employing only 12 staff members. Regencell's financial statements reflect its early-stage status, with a net loss of $4.74 million in 2024 Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].

Investors should remain cautious about Regencell's stock due to its high-risk, high-reward nature. The company's small footprint and volatile price action continue to intrigue traders looking for dramatic upside, but the perils of rapid moves should not be overlooked. The latest rebound shows that investor appetite for high-volatility biotech stories remains strong, but questions about clinical progress, revenue generation, and regulatory milestones loom large Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].